ST Renfu announced that its holding subsidiary Yichang Renfu RFUS-188 injection recently entered a phase II clinical trial study for the treatment of acute pain. Recently, Yichang's fumidazolam injection obtained marketing approval from the UK Medicines and Health Products Administration.

Zhitongcaijing · 3d ago
ST Renfu announced that its holding subsidiary Yichang Renfu RFUS-188 injection recently entered a phase II clinical trial study for the treatment of acute pain. Recently, Yichang's fumidazolam injection obtained marketing approval from the UK Medicines and Health Products Administration.